Literature DB >> 18836773

Canis familiaris telomerase reverse transcriptase undergoes alternative splicing.

Katerina Angelopoulou1, Michael Zavlaris, Nikolaos Papaioannou, Ioannis Vlemmas.   

Abstract

The enzyme telomerase is essential for cell proliferation and tumorigenesis. Telomerase reverse transcriptase (TERT) represents the catalytic subunit of the enzyme. In humans, TERT expression is regulated by several different mechanisms, including alternative splicing. Canis familiaris TERT (dogTERT) has been shown to have a high level of sequence similarity with human TERT, indicating that the dog may represent a suitable animal model for telomerase studies. In the present report we sought to investigate whether dogTERT undergoes alternative splicing. During the analysis of canine mammary tissues (both tumor and paired adjacent to the tumor normal tissues) for dogTERT expression by RT-PCR, we identified eight samples-one tumor and seven adjacent normal-which gave PCR products of unexpected sizes. DNA sequencing revealed two insertions (175 and 28 bp long) and two deletions (17 and 32 bp long), which were encountered in different combinations and gave rise to five different transcripts. The generation of all variants could be explained by the employment of alternative splicing sites within dogTERT genomic sequences. The 175-bp and 28-bp insertions, identified between exons 7 and 8 and between 8 and 9, respectively, constituted unspliced sequences of introns 7 and 8, respectively. Both deletions originated from exon 8 sequence removals due to alternative splicing. All five variants encoded truncated proteins, which lacked essential motifs for reverse transcription and might have thus lost their ability to compose active telomerase enzymes. This is the first identification of alternative splicing events within dogTERT. The results presented here may provide the basis for more thorough studies on the regulation of telomerase activity in canine normal and cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836773     DOI: 10.1007/s00335-008-9144-7

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  31 in total

Review 1.  Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT).

Authors:  J C Poole; L G Andrews; T O Tollefsbol
Journal:  Gene       Date:  2001-05-16       Impact factor: 3.688

2.  Effect of antineoplastic agents on the expression of human telomerase reverse transcriptase beta plus transcript in MCF-7 cells.

Authors:  Tonia Spiropoulou; Lisa Ferekidou; Katerina Angelopoulou; Aliki Stathopoulou; Maroulio Talieri; Evi S Lianidou
Journal:  Clin Biochem       Date:  2004-04       Impact factor: 3.281

Review 3.  Telomerase: a potential diagnostic and therapeutic tool in canine oncology.

Authors:  D J Argyle; L Nasir
Journal:  Vet Pathol       Date:  2003-01       Impact factor: 2.221

4.  Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells.

Authors:  X Yi; J W Shay; W E Wright
Journal:  Nucleic Acids Res       Date:  2001-12-01       Impact factor: 16.971

5.  Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT).

Authors:  M Wick; D Zubov; G Hagen
Journal:  Gene       Date:  1999-05-17       Impact factor: 3.688

6.  Cellular proliferative and telomerase activity in canine mammary gland tumors.

Authors:  Y Funakoshi; H Nakayama; K Uetsuka; R Nishimura; N Sasaki; K Doi
Journal:  Vet Pathol       Date:  2000-03       Impact factor: 2.221

7.  Measurement of telomerase activity in dog tumors.

Authors:  M Yazawa; M Okuda; A Setoguchi; R Nishimura; N Sasaki; A Hasegawa; T Watari; H Tsujimoto
Journal:  J Vet Med Sci       Date:  1999-10       Impact factor: 1.267

8.  hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.

Authors:  M Meyerson; C M Counter; E N Eaton; L W Ellisen; P Steiner; S D Caddle; L Ziaugra; R L Beijersbergen; M J Davidoff; Q Liu; S Bacchetti; D A Haber; R A Weinberg
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

9.  Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene.

Authors:  Hisashi Hisatomi; Kazuma Ohyashiki; Junko H Ohyashiki; Kumi Nagao; Taichi Kanamaru; Hiroyuki Hirata; Nozomu Hibi; Yutaka Tsukada
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

10.  Development of a highly sensitive RT-PCR luminometric hybridization assay for human telomerase reverse-transcriptase beta-plus transcript.

Authors:  Katerina Angelopoulou; Tonia Spiropoulou; Aliki Stathopoulou; Dimitris Dimitroulopoulos; Nikos Malamos; Vassilis Georgoulias; Emanouil Paraskevas; Evi S Lianidou
Journal:  Anticancer Res       Date:  2003 Nov-Dec       Impact factor: 2.480

View more
  3 in total

1.  A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma.

Authors:  Daniela Peruzzi; Alessandra Gavazza; Giuseppe Mesiti; George Lubas; Elisa Scarselli; Antonella Conforti; Claus Bendtsen; Gennaro Ciliberto; Nicola La Monica; Luigi Aurisicchio
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

Review 2.  Telomerase regulation.

Authors:  Catherine Cifuentes-Rojas; Dorothy E Shippen
Journal:  Mutat Res       Date:  2011-10-18       Impact factor: 2.433

Review 3.  Alternative Splicing of Human Telomerase Reverse Transcriptase (hTERT) and Its Implications in Physiological and Pathological Processes.

Authors:  Anna A Plyasova; Dmitry D Zhdanov
Journal:  Biomedicines       Date:  2021-05-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.